Colchicine renal impairment — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Do not supply until prescriber review because toxicity risk is high in severe renal impairment and with clarithromycin
Colchicine has a narrow therapeutic index and toxicity risk rises in severe renal impairment. Clarithromycin can markedly increase colchicine exposure through CYP3A4/P-gp inhibition. Severe toxicity can include gastrointestinal symptoms, myelosuppression and multiorgan failure. The prescriber should review therapy urgently before supply.
Reference: BNF